Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes.

Catherine L Wetzel Thomas Lee SuttonStuart GardinerMaryam FarinolaNathalie JohnsonJennifer R Garreau

Published in: Journal of surgical oncology (2021)

The loss of HER2-positivity following NAT is not associated with worse 5-year RFS or OS. We do not recommend retesting HER2 status following NAT for the purpose of clinical management; these patients should complete targeted adjuvant therapy.

Keyphrases

rectal cancer
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
lymph node
prostate cancer
cancer therapy
squamous cell carcinoma
patient reported outcomes
drug delivery
robot assisted